Literature DB >> 8862693

Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.

I Juhan-Vague1, M C Alessi, P Vague.   

Abstract

Disturbances of the haemostatic system may favour the development of vascular damage and the final occlusion events in the progress of coronary heart disease (CHD). It has been shown recently in epidemiological studies, that increased concentration of several factors, mainly fibrinogen, factor VII, von Willebrand factor (vWF), and the fibrinolytic variables plasminogen activator inhibitor 1 (PAI-1) and tissue plasminogen activator (t-PA), can be considered as risk factors for CHD. As morbidity and mortality through coronary atherosclerosis are higher in type 2 diabetic patients than in nondiabetic subjects and as insulin resistance represents a situation which favours the development of atherothrombosis, evaluation of the haemostatic factors which are recognized as risk factors may be interesting to consider in these situations. In fact, it has been shown that the fibrinolytic parameters PAI-1 and t-PA antigen are strongly related to the metabolic disorder of insulin resistance, whereas the link with fibrinogen, factor VII, and vWF remains weak. Many cross-sectional studies conducted in different populations have shown that PAI-1 and t-PA antigen (which represents t-PA/PAI-1 complexes) are strongly correlated with insulin, triglyceride, high-density lipoprotein (HDL) cholesterol, body mass index, walst-to-hip ratio and blood pressure, and that the improvement of insulin resistance improves in parallel the metabolic abnormalities and the concentration of the fibrinolytic parameters. Attempts at explaining the elevated PAI-1 and t-PA antigen levels in the insulin resistance syndrome have involved many clinical and in vitro studies, in which the role of insulin, insulin propeptides, very-low-density lipoprotein (VLDL) triglyceride, insulin resistance per se, glucose, and adipose tissue have successively been analysed and the main results of these studies are presented in this review. Due to recent experimental data from animal models of thrombosis, a pathogenic role of decreased fibrinolytic activity or increased PAI-1 levels can be proposed and could play a role in the development of vascular disease in subjects with Type 2 diabetes or insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862693     DOI: 10.3109/07853899608999095

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  19 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.

Authors:  L Maria Belalcazar; Christie M Ballantyne; Wei Lang; Steven M Haffner; Julia Rushing; Dawn C Schwenke; F Xavier Pi-Sunyer; Russell P Tracy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-21       Impact factor: 8.311

3.  Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Ayokanmi Adeniyi; Aaron R Folsom; Frederick L Brancati; Moise Desvorieux; James S Pankow; Herman Taylor
Journal:  J Natl Med Assoc       Date:  2002-12       Impact factor: 1.798

4.  Successful revascularization of acute carotid stent thrombosis by facilitated thrombolysis.

Authors:  Sabine Steiner-Böker; Manfred Cejna; Christian Nasel; Erich Minar; Christoph W Kopp
Journal:  AJNR Am J Neuroradiol       Date:  2004-09       Impact factor: 3.825

5.  Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.

Authors:  H Hämäläinen; T Rönnemaa; A Virtanen; J Lindström; J G Eriksson; T T Valle; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Rastas; S Aunola; M Uusitupa; J Tuomilehto
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

6.  Insulin resistance is associated with at least threefold increased risk for prothrombotic state in severely obese youngsters.

Authors:  Assimina Galli-Tsinopoulou; Ioannis Kyrgios; Ioanna Maggana; Eleni Z Giannopoulou; Eleni P Kotanidou; Charilaos Stylianou; Emmanouil Papadakis; Ioannis Korantzis; George Varlamis
Journal:  Eur J Pediatr       Date:  2010-12-08       Impact factor: 3.183

7.  Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension.

Authors:  Carlos Zamarrón; Jorge Ricoy; Alberto Riveiro; Francisco Gude
Journal:  Lung       Date:  2008-03-11       Impact factor: 2.584

8.  Tissue factor gene expression in the adipose tissues of obese mice.

Authors:  F Samad; M Pandey; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

9.  Effect of Lacidipine on Blood Pressure and Endothelial Function in Mild-to-Moderate Essential Hypertension Patients With Diabetes in Korea.

Authors:  Dae-Hee Kim; Il-Young Oh; Hae-Young Lee; Yong-Jin Kim; Hyo-Soo Kim; Cheol-Ho Kim; Byung-Hee Oh; Kwon-Sam Kim; Doo-Il Kim; Young-Dae Kim; Kyu-Hyung Ryu; Si-Hoon Park; Sang-Hong Baek; Dong-Gu Shin; Wan Joo Shim; Tae-Hoon Ahn; Seok-Kyu Oh; Seung-Hwan Lee; Sung-Yun Lee; Myung-Ho Jeong; Wook-Sung Chung; Jun-Young Jeong; So-Yeon Choi; Si-Wan Choi; Min-Su Hyon
Journal:  Korean Circ J       Date:  2010-12-31       Impact factor: 3.243

Review 10.  Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.

Authors:  William B Hillegass; Brigitta C Brott; James C Dobbs; Silvio E Papapietro; Vijay K Misra; Gilbert J Zoghbi
Journal:  Vasc Health Risk Manag       Date:  2011-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.